百花医药表示，由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意 见，本着审慎的原则，决定终止本次控制权变更事项。公司目前各项经营情况正常，终止筹划控制权变 更事项不会对公司经营业绩和财务状况产生重大不利影响。 北京商报讯（记者 丁宁）1月6日晚间，百花医药（600721）发布公告称，因公司控股股东、实际控制 人米在齐、米恩华、杨小玲终止筹划本次控制权变更事项，经公司向上交所申请，公司股票将于1月7日 开市起复牌。 ...

智通財經APP訊，百花醫藥(600721.SH)公告，公司控股股東、實際控制人米在齊先生、米恩華先生、 楊小玲女士終止籌劃控制權變更事項。公司股票將於2026年1月7日(星期三)開市起復牌。 ...

新疆百花村医药集团股份有限公司 重要内容提示： 证券停复牌情况：适用 因新疆百花村医药集团股份有限公司（以下简称"百花医药"或"公司"） 控股股东、实际控制人米在齐先生、米恩华先生、杨小玲女士终止筹划本次控制 权变更事项,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600721 | 百花医药 | A 股 | 复牌 | | | 2026/1/6 | 2026/1/7 | 一、停牌情况概述 因公司控股股东、实际控制人米在齐先生、米恩华先生、杨小玲女士正在筹 划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。鉴于该事项正 在洽谈当中，尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造 成公司股价异常波动，经公司向上海证券交易所申请，公司股票（证券代码：600721， 证券简称：百花医药）自 2025 年 12 月 29 日（星期一）开市起停牌，预计停牌时 间不超过 2 个交易日。停牌期间，上述事项仍 ...

百花医药公告，因公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意见， 决定终止本次控制权变更事项。公司股票将于2026年1月7日开市起复牌。 ...

格隆汇1月6日丨百花医药（维权）(600721.SH)公布，因控股股东、实际控制人与交易对方未就控制权 变更相关重大事项达成一致意见，决定终止筹划控制权变更事项。公司股票自2026年1月7日起复牌。公 司目前各项经营情况正常，终止筹划控制权变更事项不会对公司经营业绩和财务状况产生重大不利影 响。 ...

Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]

截至本公告披露日，上述事项仍处于筹划之中，公司控股股东、实际控制人正与相关方积极推进本次事 项的各项工作，公司预计无法在2025年12月31日（星期三）开市起复牌。根据《上海证券交易所股票上 市规则》《上海证券交易所上市公司自律监管指引第4号——停复牌》等有关规定，经公司向上海证券 交易所申请，本公司股票将于2025年12月31日（星期三）开市起继续停牌，预计继续停牌时间不超过3 个交易日。 格隆汇12月30日丨百花医药（维权）(600721.SH)公布，公司于2025年12月26日收到公司控股股东、实 际控制人米在齐先生、米恩华先生、杨小玲女士的通知，米在齐先生、米恩华先生、杨小玲女士正在筹 划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-047 新疆百花村医药集团股份有限公司 关于筹划控制权变更事项继续停牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 媒体披露的《新疆百花村医药集团股份有限公司关于筹划控制权变更事项的停牌 公告》（公告编号：2025-046）。 截至本公告披露日，上述事项仍处于筹划之中，公司控股股东、实际控制人 正与相关方积极推进本次事项的各项工作，公司预计无法在 2025 年 12 月 31 日 （星期三）开市起复牌。根据《上海证券交易所股票上市规则》《上海证券交易 所上市公司自律监管指引第 4 号——停复牌》等有关规定，经公司向上海证券交 易所申请，本公司股票将于 2025 年 12 月 31 日（星期三）开市起继续停牌，预 计继续停牌时间不超过 3 个交易日。 停牌期间，公司将根据上述事项进展情况，严格按照有关法律法规的规定和 要求履行信息披露义务。待上述事项确定后，公司将及时发布相关公告并申请公 ...

每经AI快讯，12月30日，百花医药（600721）公告，公司股票自2025年12月31日开市起继续停牌，预 计停牌时间不超过3个交易日，因公司控股股东、实际控制人米在齐先生、米恩华先生、杨小玲女士正 在筹划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。目前相关方正积极推进本次交易 工作，尚存在不确定性。停牌期间，公司将严格按照有关法律法规的规定和要求履行信息披露义务。待 事项确定后，公司将及时发布相关公告并申请股票复牌。敬请广大投资者关注公司后续公告，并注意投 资风险。 ...

百花医药公告，公司控股股东、实际控制人正在筹划公司股份协议转让事宜，该事项可能导致公司控制 权发生变更。为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动，公司股票将于2025 年12月31日开市起继续停牌，预计继续停牌时间不超过3个交易日。 ...